Number and proportion of potentially eligible patients in OpenSAFELY-TPP who received treatment for covid-19 between 16 December 2021 and 28 April 2022, by high risk group and treatment type
| High risk group | Eligible (No) | Covid-19 treatment | |||||||||||
| All | Paxlovid | Sotrovimab | Remdesivir | Molnupiravir | Casirivimab/imdevimab | ||||||||
| No | % (95% CI) | No | % (95% CI) | No | % (95% CI) | No | % (95% CI) | No | % (95% CI) | No | % (95% CI) | ||
| All | 93 870 | 19 040 | 20 (20 to 21) | 4680 | 25 (24 to 25) | 9660 | 51 (50 to 51) | 30 | 0 (0 to 0) | 4620 | 24 (24 to 25) | 50 | 0 (0 to 0) |
| Immune mediated inflammatory disorders | 37 140 | 7910 | 21 (21 to 22) | 1300 | 16 (16 to 17) | 4400 | 56 (55 to 57) | 10 | 0 (0 to 0) | 2170 | 27 (26 to 28) | 20 | 0 (0 to 0) |
| Immune deficiencies* | 18 060 | 3230 | 18 (17 to 18) | 810 | 25 (24 to 27) | 1560 | 48 (47 to 50) | <8 | — | 850 | 26 (25 to 28) | 10 | 0 (0 to 1) |
| Solid cancer | 15 700 | 2810 | 18 (17 to 18) | 400 | 14 (13 to 16) | 1640 | 58 (57 to 60) | <8 | — | 770 | 27 (26 to 29) | 10 | 0 (0 to 1) |
| Rare neurological conditions | 11 090 | 2740 | 25 (24 to 26) | 860 | 31 (30 to 33) | 1230 | 45 (43 to 47) | <8 | — | 640 | 23 (22 to 25) | <8 | — |
| Haematological diseases and recipients of stem cell transplants | 8430 | 2760 | 33 (32 to 34) | 460 | 17 (15 to 18) | 1600 | 58 (56 to 60) | <8 | — | 680 | 25 (23 to 26) | 10 | 0 (0 to 1) |
| Recepients of solid organ transplants | 6260 | 2070 | 33 (32 to 34) | 60 | 3 (2 to 4) | 1480 | 71 (70 to 73) | <8 | — | 510 | 25 (23 to 26) | <8 | — |
| Renal disease | 5860 | 2020 | 34 (33 to 36) | <8 | — | 1460 | 72 (70 to 74) | <8 | — | 540 | 27 (25 to 29) | <8 | — |
| Liver disease | 5110 | 800 | 16 (15 to 17) | 40 | 5 (3 to 7) | 510 | 64 (60 to 67) | <8 | — | 250 | 31 (28 to 34) | <8 | — |
| Down’s syndrome | 2310 | 460 | 20 (18 to 22) | 140 | 30 (26 to 35) | 160 | 35 (30 to 39) | <8 | — | 160 | 35 (30 to 39) | <8 | — |
| High risk group unknown | 1330 | 1330 | 100 (100 to 100) | 1280 | 96 (95 to 97) | 50 | 4 (3 to 5) | <8 | — | <8 | — | <8 | — |
| Immunosuppression due to HIV or AIDS | 570 | 340 | 60 (56 to 64) | 10 | 3 (1 to 5) | 170 | 50 (45 to 55) | <8 | — | 160 | 47 (42 to 52) | <8 | — |
CI=confidence interval.Patients can appear in more than one risk group. Patient numbers of 0-7 are shown as <8, with remaining numbers rounded to the nearest 10; as a result percentages might not add up to 100%. High risk groups are arranged in descending order, according to number of potentially eligible patients.
*In the publication on which this analysis is based, this group was labelled “primary immune deficiency,”10 but in the present study this group has been labelled according to the current NHS Digital policy (version 5).